Medpacto: 투자판단관련주요경영사항(임상시험계획변경승인신청) (재발성, 불응성 또는 진행성 골육종 환자 대상 백토서팁 단독 요법 제1/2상 임상시험계획(IND) 미국 식품의약국(FDA) 변경승인신청)
AI reading
★★★ Neutral · Material event
Application for IND Amendment for Vactosertib Clinical Trial in Osteosarcoma Patients
An AI model read the opening section of the filing and rated it relative to the company's size. It can be wrong, so check the original filing on DART (Korean).
Other filings by Medpacto
- 09.18 ★★ [Amended] Material Management Matter: Application for IND Amendment for Phase 1/2 Clinical Trial of Vactosertib Monotherapy in Patients with Relapsed, Refractory, or Progressive Osteosarcoma (MFDS)
- 09.18 ★★ [Amended] Material Management Matter: Approval of IND Amendment for Phase 1/2 Clinical Trial of Vactosertib Monotherapy in Patients with Relapsed, Refractory, or Progressive Osteosarcoma (MFDS)
- 09.15 ★★★ Approval of IND Amendment for Vactosertib Monotherapy Clinical Trial in Osteosarcoma Patients
For information only. Not investment advice.